Headlines

Novo Nordisk (NOVOB DC) to present new CagriSema and zenagamtide data as it advances its cardiometabolic pipeline at the American Diabetes Association’s 2026 Scientific Sessions

Newsquawk Staff ·

Novo Nordisk (NOVOB DC) to present new CagriSema and zenagamtide data as it advances its cardiometabolic pipeline at the American Diabetes Association’s 2026 Scientific Sessions.

Related headlines